|
|
|
|
| LEADER |
02301nmm a2200265 u 4500 |
| 001 |
EB000388987 |
| 003 |
EBX01000000000000000242040 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9783642289651
|
| 100 |
1 |
|
|a Wendt, Michael D.
|e [editor]
|
| 245 |
0 |
0 |
|a Protein-Protein Interactions
|h Elektronische Ressource
|c edited by Michael D. Wendt
|
| 250 |
|
|
|a 1st ed. 2012
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2012, 2012
|
| 300 |
|
|
|a XVIII, 262 p
|b online resource
|
| 505 |
0 |
|
|a Protein-Protein Interactions as Drug Targets -- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics -- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer -- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection -- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus -- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces -- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
|
| 653 |
|
|
|a Chemistry
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Topics in Medicinal Chemistry
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-28965-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-28965-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 540
|
| 520 |
|
|
|a Michael D. Wendt Protein-Protein Interactions as Drug Targets Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics Kurt Deshayes , Jeremy Murray , Domagoj Vucic The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto Protein-Protein Interaction Targets to Inhibit HIV-1 Infection Nicholas A. Meanwell , David R. Langley Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces Michael D. Wendt The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
|